U.S. pharma large copyright scrapped two experimental weight loss pills past year—a once-day-to-day tablet, lotiglipron, as a consequence of elevated liver enzymes and also a twice-day by day tablet, danuglipron, due to solid Unwanted effects—but CEO Albert Bourla has claimed the company is set to “Participate in and win” in the obesity spa